

Klaus Kopka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9501379/publications.pdf>

Version: 2024-02-01

225
papers

12,980
citations

28190

55
h-index

26548

107
g-index

248
all docs

248
docs citations

248
times ranked

8167
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 197-209. | 3.3 | 866 |
| 2 | ²²⁵ Ac-PSMA-617 for PSMA-Targeted α -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1941-1944. | 2.8 | 741 |
| 3 | 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1014-1024. | 3.3 | 589 |
| 4 | PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷ Lu-Labeled PSMA-617. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1170-1176. | 2.8 | 475 |
| 5 | Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 914-920. | 2.8 | 451 |
| 6 | Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1258-1268. | 3.3 | 425 |
| 7 | F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 678-688. | 3.3 | 421 |
| 8 | The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1697-1705. | 2.8 | 332 |
| 9 | Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. <i>Pharmaceuticals</i> , 2014, 7, 779-796. | 1.7 | 323 |
| 10 | Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1280-1292. | 3.3 | 319 |
| 11 | EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544. | 3.3 | 265 |
| 12 | Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 42-51. | 3.3 | 244 |
| 13 | Detection Efficacy of ¹⁸ F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 362-368. | 2.8 | 238 |
| 14 | Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. <i>Pharmaceuticals</i> , 2019, 12, 114. | 1.7 | 218 |
| 15 | Scintigraphic Imaging of Matrix Metalloproteinase Activity in the Arterial Wall In Vivo. <i>Circulation</i> , 2004, 109, 2554-2559. | 1.6 | 211 |
| 16 | The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 79S-89S. | 2.8 | 200 |
| 17 | 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 34-41. | 3.3 | 194 |
| 18 | Preclinical Evaluation of ¹⁸ F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 425-431. | 2.8 | 186 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | [¹⁷⁷ Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 987-988. | 3.3 | 155 |
| 20 | New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. Clinical Cancer Research, 2016, 22, 9-15. | 3.2 | 155 |
| 21 | Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 1761-1775. | 2.9 | 150 |
| 22 | Comparison of hybrid ⁶⁸ Ga-PSMA PET/MRI and ⁶⁸ Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 70-83. | 3.3 | 148 |
| 23 | Radiation dosimetry of ⁶⁸ Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1611-1620. | 3.3 | 143 |
| 24 | Intraindividual Comparison of ¹⁸ F-PSMA-1007 and ¹⁸ F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. Journal of Nuclear Medicine, 2018, 59, 1076-1080. | 2.8 | 140 |
| 25 | Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in ⁶⁸ Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 776-787. | 3.3 | 124 |
| 26 | Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2045-2054. | 3.3 | 116 |
| 27 | Glu-Ureido- Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. Journal of Nuclear Medicine, 2017, 58, 17S-26S. | 2.8 | 111 |
| 28 | PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸ Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1794-1800. | 3.3 | 109 |
| 29 | The Clinical Impact of Additional Late PET/CT Imaging with ⁶⁸ Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 750-755. | 2.8 | 105 |
| 30 | ⁶⁸ Ga or ¹⁸ F for Prostate Cancer Imaging?. Journal of Nuclear Medicine, 2017, 58, 687-688. | 2.8 | 105 |
| 31 | Intra-individual comparison of ⁶⁸ Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1400-1406. | 3.3 | 101 |
| 32 | PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 293-298. | 2.8 | 100 |
| 33 | Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. Science Translational Medicine, 2016, 8, 364ra152. | 5.8 | 94 |
| 34 | Clinical Translation and First In-Human Use of [⁴⁴ Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. Theranostics, 2017, 7, 4359-4369. | 4.6 | 94 |
| 35 | Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate, 2014, 74, 659-668. | 1.2 | 93 |
| 36 | Intraindividual Comparison of ¹⁸ F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. Journal of Nuclear Medicine, 2017, 58, 1805-1810. | 2.8 | 91 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | PSMA-11â€‘Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 639-645. | 2.8 | 89 |
| 38 | ⁶⁸ Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e473-e479. | 0.7 | 86 |
| 39 | Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET. <i>Current Medicinal Chemistry</i> , 2006, 13, 2819-2838. | 1.2 | 84 |
| 40 | Procedures for the GMP-Compliant Production and Quality Control of [¹⁸ F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. <i>Pharmaceuticals</i> , 2017, 10, 77. | 1.7 | 83 |
| 41 | Encapsulating ¹¹¹ In in Nanocontainers for Scintigraphic Imaging: Synthesis, Characterization, and In Vivo Biodistribution. <i>ACS Nano</i> , 2010, 4, 342-348. | 7.3 | 82 |
| 42 | ¹⁸ F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1929-1930. | 3.3 | 81 |
| 43 | Development and dosimetry of ²⁰³ Pb/ ²¹² Pb-labelled PSMA ligands: bringing â€‘the leadâ€‘into PSMA-targeted alpha therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1081-1091. | 3.3 | 77 |
| 44 | Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. <i>Nuclear Medicine and Biology</i> , 2004, 31, 257-267. | 0.3 | 72 |
| 45 | Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 405-418. | 2.5 | 72 |
| 46 | Fluorinated Isatin Derivatives. Part 2. New <i>N</i> -Substituted 5-Pyrrolidinylsulfonyl Isatins as Potential Tools for Molecular Imaging of Caspases in Apoptosis. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3484-3495. | 2.9 | 71 |
| 47 | Whole-body PET/CT with ¹¹ C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with ¹²³ I-MIBG SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1635-42. | 2.8 | 69 |
| 48 | Novel Fluorinated Derivatives of the Broad-Spectrum MMP Inhibitors <i>N</i> -Hydroxy-2(<i>R</i>)-[[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picoyl)-amino]-3-methyl-butanamide as Potential Tools for the Molecular Imaging of Activated MMPs with PET. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5752-5764. | 2.9 | 68 |
| 49 | Repeated ¹⁷⁷ Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. <i>Journal of Nuclear Medicine</i> , 2018, 59, 459-465. | 2.8 | 68 |
| 50 | 5-Pyrrolidinylsulfonyl Isatins as a Potential Tool for the Molecular Imaging of Caspases in Apoptosis. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6704-6715. | 2.9 | 63 |
| 51 | Multimodal Imaging Reveals Temporal and Spatial Microglia and Matrix Metalloproteinase Activity after Experimental Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1711-1721. | 2.4 | 62 |
| 52 | A new ¹⁸ F-labelled derivative of the MMP inhibitor CGS 27023A for PET: Radiosynthesis and initial small-animal PET studies. <i>Applied Radiation and Isotopes</i> , 2009, 67, 606-610. | 0.7 | 60 |
| 53 | Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeutics. <i>Theranostics</i> , 2016, 6, 1085-1095. | 4.6 | 60 |
| 54 | Radiofluorinated Pyrimidineâ€‘2,4,6â€‘triones as Molecular Probes for Noninvasive MMPâ€‘Targeted Imaging. <i>ChemMedChem</i> , 2010, 5, 777-789. | 1.6 | 59 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | C-5-Disubstituted Barbiturates as Potential Molecular Probes for Noninvasive Matrix Metalloproteinase Imaging. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3400-3409. | 2.9 | 58 |
| 56 | ⁶⁸ Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1288-1299. | 3.3 | 58 |
| 57 | PET/CT studies of multiple myeloma using ¹⁸ F-FDG and ¹⁸ F-NaF: comparison of distribution patterns and tracers' pharmacokinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1343-1353. | 3.3 | 55 |
| 58 | Biochemical Recurrence of Prostate Cancer: Initial Results with [¹⁸ F]PSMA-1007 PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 632-635. | 2.8 | 55 |
| 59 | Investigation of the halo-artifact in ⁶⁸ Ga-PSMA-11-PET/MRI. <i>PLoS ONE</i> , 2017, 12, e0183329. | 1.1 | 53 |
| 60 | Synthesis and Evaluation of a Novel Fluorescent Photoprobe for Imaging Matrix Metalloproteinases. <i>Bioconjugate Chemistry</i> , 2008, 19, 1001-1008. | 1.8 | 51 |
| 61 | A New Generation of Radiofluorinated Pyrimidine-2,4,6-triones as MMP-Targeted Radiotracers for Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 223-232. | 2.9 | 49 |
| 62 | ⁶⁸ Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 234-240. | 2.8 | 49 |
| 63 | Fluorinated isatin derivatives. Part 1: Synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatins as potent caspase-3 and -7 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2680-2688. | 1.4 | 48 |
| 64 | Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer. <i>Bioconjugate Chemistry</i> , 2016, 27, 737-751. | 1.8 | 48 |
| 65 | ¹⁸ F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e497-e499. | 0.9 | 47 |
| 66 | A Closer Look at the Bromine-Lithium Exchange with <i>tert</i> -Butyllithium in an Aryl Sulfonamide Synthesis. <i>Organic Letters</i> , 2013, 15, 2954-2957. | 2.4 | 45 |
| 67 | A New Class of Highly Potent Matrix Metalloproteinase Inhibitors Based on Triazole-Substituted Hydroxamates: (Radio)Synthesis and in Vitro and First in Vivo Evaluation. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4714-4727. | 2.9 | 43 |
| 68 | On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion. <i>Nuclear Medicine and Biology</i> , 2021, 93, 19-21. | 0.3 | 43 |
| 69 | Improving the Imaging Contrast of ⁶⁸ Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. <i>Bioconjugate Chemistry</i> , 2017, 28, 2485-2492. | 1.8 | 40 |
| 70 | Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1-8. | 3.3 | 39 |
| 71 | Response Prediction of ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. <i>Journal of Nuclear Medicine</i> , 2020, 61, 689-695. | 2.8 | 39 |
| 72 | Treatment response evaluation with ¹⁸ F-FDG PET/CT and ¹⁸ F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 50-62. | 3.3 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice. Archives of Toxicology, 2016, 90, 839-851. | 1.9 | 36 |
| 74 | Inverse 1,2,3-Triazole-1-yl-ethyl Substituted Hydroxamates as Highly Potent Matrix Metalloproteinase Inhibitors: (Radio)synthesis, in Vitro and First in Vivo Evaluation. Journal of Medicinal Chemistry, 2013, 56, 6858-6870. | 2.9 | 34 |
| 75 | ⁶⁸ Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 904-912. | 3.3 | 34 |
| 76 | Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov. Pharmaceuticals, 2020, 13, 12. | 1.7 | 34 |
| 77 | Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. Cancer Research, 2019, 79, 841-852. | 0.4 | 33 |
| 78 | Synthesis and Evaluation of a Novel Hydroxamate Based Fluorescent Photoprobe for Imaging of Matrix Metalloproteinases. Bioconjugate Chemistry, 2009, 20, 904-912. | 1.8 | 32 |
| 79 | Simultaneous whole-body ¹⁸ F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 340-347. | 3.3 | 32 |
| 80 | Early Assessment of the Efficacy of Temozolomide Chemotherapy in Experimental Glioblastoma Using [¹⁸ F]FLT-PET Imaging. PLoS ONE, 2013, 8, e67911. | 1.1 | 32 |
| 81 | Intraindividual comparison of [⁶⁸ Ga]-Ga-PSMA-11 and [¹⁸ F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Research, 2021, 11, 109. | 1.1 | 32 |
| 82 | NADH:Cytochrome <i>b₅</i> Reductase and Cytochrome <i>b₅</i> Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[a]pyrene. Chemical Research in Toxicology, 2016, 29, 1325-1334. | 1.7 | 31 |
| 83 | Non-Invasive Molecular Imaging of α -Adrenoceptors In Vivo: Perspectives for PET-Radioligands. Current Medicinal Chemistry, 2005, 12, 2057-2074. | 1.2 | 30 |
| 84 | Metabolite Identification of a Radiotracer by Electrochemistry Coupled to Liquid Chromatography with Mass Spectrometric and Radioactivity Detection. Analytical Chemistry, 2011, 83, 5415-5421. | 3.2 | 29 |
| 85 | Robust augmented reality guidance with fluorescent markers in laparoscopic surgery. International Journal of Computer Assisted Radiology and Surgery, 2016, 11, 899-907. | 1.7 | 29 |
| 86 | Sequential scintigraphic strategy for the differentiation of brain tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 550-558. | 3.3 | 27 |
| 87 | A Fluorescent Photoprobe for the Imaging of Endothelin Receptors. Bioconjugate Chemistry, 2007, 18, 685-694. | 1.8 | 27 |
| 88 | ⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1949-1955. | 2.8 | 27 |
| 89 | Monomeric and Dimeric ⁶⁸ Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs). Journal of Medicinal Chemistry, 2018, 61, 2062-2074. | 2.9 | 27 |
| 90 | Design of new ¹²⁵ I-selective adrenoceptor ligands as potential radioligands for in vivo imaging. Bioorganic and Medicinal Chemistry, 2003, 11, 3513-3527. | 1.4 | 26 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | The MMP inhibitor (R)-2-(N-benzyl-4-(2-[¹⁸ F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis. <i>Applied Radiation and Isotopes</i> , 2011, 69, 862-868. | 0.7 | 26 |
| 92 | Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1179-1187. | 3.3 | 26 |
| 93 | Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice. <i>Archives of Toxicology</i> , 2018, 92, 1625-1638. | 1.9 | 26 |
| 94 | Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. <i>Journal of Nuclear Medicine</i> , 2020, 61, 46-50. | 2.8 | 26 |
| 95 | ¹⁸ F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 592-602. | 3.3 | 26 |
| 96 | Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging. <i>Pharmaceuticals</i> , 2020, 13, 272. | 1.7 | 25 |
| 97 | Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 143-151. | 3.3 | 25 |
| 98 | Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study. <i>Cancers</i> , 2021, 13, 1974. | 1.7 | 25 |
| 99 | Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPRINHA-accelerated MR-based attenuation correction. <i>European Journal of Radiology</i> , 2017, 96, 12-20. | 1.2 | 24 |
| 100 | Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers — A Status Report. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009, 9, 968-985. | 0.9 | 23 |
| 101 | Synthesis of new fluorinated, 2-substituted 5-pyrrolidinylsulfonyl isatin derivatives as caspase-3 and caspase-7 inhibitors: Nonradioactive counterparts of putative PET-compatible apoptosis imaging agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2025-2036. | 1.4 | 23 |
| 102 | A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. <i>Oncoimmunology</i> , 2019, 8, 1659095. | 2.1 | 23 |
| 103 | Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 70-79. | 2.8 | 23 |
| 104 | The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2057-2058. | 3.3 | 23 |
| 105 | Kinetics of 3-[¹²³ I]iodo-L-tyrosine transport in rat C6 glioma cells. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1274-1278. | 2.2 | 22 |
| 106 | Molecular Imaging of Cardiac Sympathetic Innervation by ¹¹ C- <i>m</i> HED and PET: From Man to Mouse?. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1269-1276. | 2.8 | 22 |
| 107 | Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo. <i>Toxicology</i> , 2016, 344-346, 7-18. | 2.0 | 22 |
| 108 | Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzantrone. <i>Archives of Toxicology</i> , 2017, 91, 1957-1975. | 1.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Radiolabeled PSMA Inhibitors. <i>Cancers</i> , 2021, 13, 6255. | 1.7 | 22 |
| 110 | Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by ^{18}F -Fluorothymidine PET and Diffusion-Weighted MR Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 983-988. | 2.8 | 21 |
| 111 | Kinetic parameters of 3-[^{123}I]iodo-L- β -methyl tyrosine ([^{123}I]IMT) transport in human GOS3 glioma cells. <i>Nuclear Medicine and Biology</i> , 2001, 28, 293-297. | 0.3 | 20 |
| 112 | Fluorinated isatin derivatives. Part 3. New side-chain fluoro-functionalized pyrrolidinyl sulfonyl isatins as potent caspase-3 and -7 inhibitors. <i>Future Medicinal Chemistry</i> , 2009, 1, 969-989. | 1.1 | 19 |
| 113 | Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 307-321. | 2.9 | 19 |
| 114 | Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 168-180. | 0.4 | 19 |
| 115 | ^{68}Ga , ^{44}Sc and ^{177}Lu -labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 28. | 1.8 | 19 |
| 116 | New matrix metalloproteinase inhibitors based on ^{18}F -fluorinated β -aminocarboxylic and β -aminohydroxamic acids. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3809-3818. | 1.4 | 18 |
| 117 | Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas. <i>Radiation Oncology</i> , 2017, 12, 174. | 1.2 | 18 |
| 118 | Development of PSMA-1007-Related Series of ^{18}F -Labeled Glu-Ureido-Type PSMA Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10897-10907. | 2.9 | 18 |
| 119 | Experimental techniques to study protein-surfactant interactions: New insights into competitive adsorptions via drop subphase and interface exchange. <i>Advances in Colloid and Interface Science</i> , 2022, 301, 102601. | 7.0 | 18 |
| 120 | Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. <i>Pharmaceuticals</i> , 2022, 15, 747. | 1.7 | 18 |
| 121 | Development and Evaluation of Endothelin-A Receptor (Radio)Ligands for Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 939-948. | 2.9 | 17 |
| 122 | Effects of arm truncation on the appearance of the halo artifact in ^{68}Ga -PSMA-11 (HBED-CC) PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1636-1646. | 3.3 | 17 |
| 123 | Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined ^{18}F -FDG and ^{18}F -FLT PET/CT imaging. <i>EJNMMI Research</i> , 2018, 8, 28. | 1.1 | 17 |
| 124 | Identification of Ligands and Translation to Clinical Applications. <i>Journal of Nuclear Medicine</i> , 2017, 58, 27S-33S. | 2.8 | 16 |
| 125 | Sub-100 nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha Therapy. <i>ChemistryOpen</i> , 2020, 9, 797-805. | 0.9 | 16 |
| 126 | Development of an ^{18}F -Labeled Irreversible Inhibitor of Transglutaminase 2 as Radiometric Tool for Quantitative Expression Profiling in Cells and Tissues. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3462-3478. | 2.9 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Biodistribution of a Nonpeptidic Fluorescent Endothelin a Receptor Imaging Probe. <i>Molecular Imaging</i> , 2009, 8, 7290.2009.00003. | 0.7 | 15 |
| 128 | Synthesis of Geminal Difluorides by Oxidative Desulfurization~Difluorination of Alkyl Aryl Thioethers with Halonium Electrophiles in the Presence of Fluorinating Reagents and Its Application for ¹⁸ F-Radiolabeling. <i>Journal of Organic Chemistry</i> , 2010, 75, 6086-6095. | 1.7 | 15 |
| 129 | HBED-NN: A Bifunctional Chelator for Constructing Radiopharmaceuticals. <i>Journal of Organic Chemistry</i> , 2019, 84, 7501-7508. | 1.7 | 15 |
| 130 | Impact of ¹⁸ F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1594-1599. | 2.8 | 15 |
| 131 | The impact of barium isotopes in radiopharmacy and nuclear medicine – From past to presence. <i>Nuclear Medicine and Biology</i> , 2021, 98-99, 59-68. | 0.3 | 15 |
| 132 | Synthesis and first in vivo evaluation of new selective high affinity ¹²¹ I-adrenoceptor radioligands for SPECT based on ICI 89,406. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 4117-4132. | 1.4 | 14 |
| 133 | Synthesis, binding affinity and structure~activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 2407-2422. | 1.5 | 14 |
| 134 | Synthesis, in vitro pharmacology and biodistribution studies of new PD 156707-derived ETA receptor radioligands. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1910-1917. | 1.4 | 13 |
| 135 | Synthesis of 7-Halogenated Isatin Sulfonamides: Nonradioactive Counterparts of Caspase-3/-7 Inhibitor-Based Potential Radiopharmaceuticals for Molecular Imaging of Apoptosis. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9383-9395. | 2.9 | 13 |
| 136 | Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1673-1683. | 3.3 | 13 |
| 137 | Live-cell imaging with <i>Aspergillus fumigatus</i> -specific fluorescent siderophore conjugates. <i>Scientific Reports</i> , 2020, 10, 15519. | 1.6 | 13 |
| 138 | ~Clickable~Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 710-733. | 2.9 | 13 |
| 139 | Preclinical evaluation of an ¹⁸ F-labelled ¹²¹ I-adrenoceptor selective radioligand based on ICI 89,406. <i>Nuclear Medicine and Biology</i> , 2010, 37, 517-526. | 0.3 | 12 |
| 140 | DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. <i>Mutagenesis</i> , 2019, 34, 239-244. | 1.0 | 12 |
| 141 | Synthesis, characterization and evaluation of ⁶⁸ Ga labelled monomeric and dimeric quinazoline derivatives of the HBED-CC chelator targeting the epidermal growth factor receptor. <i>Bioorganic Chemistry</i> , 2020, 100, 103855. | 2.0 | 12 |
| 142 | Characterization of 3-[¹²³ I]iodo-L- ¹ -methyl tyrosine ([¹²³ I]IMT) transport into human Ewing~sarcoma cells in vitro. <i>Nuclear Medicine and Biology</i> , 2001, 28, 123-128. | 0.3 | 11 |
| 143 | Synthesis of an ¹⁸ F-labelled high affinity ¹²¹ I-adrenoceptor PET radioligand based on ICI 89,406. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 177-195. | 0.5 | 11 |
| 144 | ¹⁸ F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases. <i>Basic Research in Cardiology</i> , 2008, 103, 131-143. | 2.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Characterization of 3-[¹²³ I]iodo-L-tyrosine transport in astrocytes of neonatal rats. Journal of Neurochemistry, 2008, 76, 97-104. | 2.1 | 11 |
| 146 | PET-compatible endothelin receptor radioligands: Synthesis and first in vitro and in vivo studies. Bioorganic and Medicinal Chemistry, 2009, 17, 7197-7208. | 1.4 | 11 |
| 147 | Synthesis, ¹⁸ F-Radiolabeling, and in Vivo Biodistribution Studies of N-Fluorohydroxybutyl Isatin Sulfonamides using Positron Emission Tomography. Journal of Medicinal Chemistry, 2013, 56, 4509-4520. | 2.9 | 11 |
| 148 | Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. Cancer Research, 2021, 81, 2234-2245. | 0.4 | 11 |
| 149 | Automated [¹⁸ F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 18. | 1.8 | 11 |
| 150 | Prognostic Significance of Amino Acid Transport Imaging in Patients with Brain Tumors. Neurosurgery, 2002, 50, 958-965. | 0.6 | 10 |
| 151 | Early Effects of Irradiation on [¹²³ I]-IMT and [¹⁸ F]-FDG Uptake in Rat C6 Glioma Cells. Strahlentherapie Und Onkologie, 2004, 180, 434-441. | 1.0 | 10 |
| 152 | Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer. European Urology, 2016, 69, 397-399. | 0.9 | 10 |
| 153 | Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic and eukaryotic expression systems. Monatshefte Für Chemie, 2017, 148, 1959-1969. | 0.9 | 10 |
| 154 | Synthesis and application of a thiol-reactive HBED-type chelator for development of easy-to-produce Ga-radiopharmaceutical kits and imaging probes. Organic and Biomolecular Chemistry, 2021, 19, 1722-1726. | 1.5 | 10 |
| 155 | Structure-Based Design, Optimization, and Development of [¹⁸ F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET. Journal of Medicinal Chemistry, 2022, 65, 9034-9049. | 2.9 | 10 |
| 156 | Ein zweikerniger Vanadium(V)-Komplex mit (1/4- ¹)- und (1/4-1/4 ²)-gebundenen Hydrazido(2-)-Liganden / A Dinuclear Vanadium(V) Complex with (1/4 ¹)- and (1/4-1/4 ²)-Bonded Hydrazido(2-) Ligands. Zeitschrift Für Naturforschung - Section B Journal of Chemical Sciences, 1996, 51, 1675-1678. | 0.3 | 9 |
| 157 | Current status and future applications of cardiac receptor imaging with positron emission tomography. Nuclear Medicine Communications, 2002, 23, 113-115. | 0.5 | 9 |
| 158 | Molecular cardiovascular imaging using scintigraphic methods. European Radiology, 2007, 17, 1422-1432. | 2.3 | 9 |
| 159 | Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability. Nuclear Medicine and Biology, 2016, 43, 424-437. | 0.3 | 9 |
| 160 | A Convenient Synthesis for HBED-CC-tris(tert-butyl ester). Synlett, 2018, 29, 1239-1243. | 1.0 | 9 |
| 161 | Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules. Journal of Nuclear Medicine, 2021, 62, 1461-1467. | 2.8 | 9 |
| 162 | Kinetics of 3- ¹ . European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1274. | 2.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 351-359. | 1.0 | 9 |
| 164 | $\text{[}^{21}\text{I}$ -Adrenoceptors in Rat Anterior Pituitary May Be Constitutively Active. Inverse Agonism of CGP 20712A on Basal $\text{[}^{3}\text{H}$]-5'-Cyclic Adenosine 5'-Monophosphate Levels. Endocrinology, 2008, 149, 2391-2402. | 1.4 | 8 |
| 165 | Influence of 4- or 5-substituents on the pyrrolidine ring of 5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin derivatives on their inhibitory activities towards caspases-3 and -7. European Journal of Medicinal Chemistry, 2013, 64, 562-578. | 2.6 | 8 |
| 166 | Diverse modifications of the 4-methylphenyl moiety of TAK-779 by late-stage Suzuki-Miyaura cross-coupling. Organic and Biomolecular Chemistry, 2014, 12, 177-186. | 1.5 | 8 |
| 167 | Novel fluorine-18 labeled 5-(1-pyrrolidinylsulfonyl)-7-azaisatin derivatives as potential PET tracers for in vivo imaging of activated caspases in apoptosis. Bioorganic and Medicinal Chemistry, 2015, 23, 5734-5739. | 1.4 | 8 |
| 168 | Integration of CT urography improves diagnostic confidence of ^{68}Ga -PSMA-11 PET/CT in prostate cancer patients. Cancer Imaging, 2017, 17, 30. | 1.2 | 8 |
| 169 | Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma. Cancers, 2021, 13, 1508. | 1.7 | 8 |
| 170 | Synthesis of (R)- and (S)-[O-methyl- ^{11}C]N-[2-[3-(2-cyano-phenoxy)-2-hydroxy-propylamino]-ethyl]-N-(4-methoxy-phenyl)-urea as candidate high affinity ^{121}I -adrenoceptor PET radioligands. Journal of Labelled Compounds and Radiopharmaceuticals, 2005, 48, 721-733. | 0.5 | 7 |
| 171 | Are [O-methyl- ^{11}C]derivatives of ICI 89,406 ^{121}I -adrenoceptor selective radioligands suitable for PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 174-185. | 3.3 | 7 |
| 172 | Syntheses of Radioiodinated Pyrimidine-2,4,6-Triones as Potential Agents for Non-Invasive Imaging of Matrix Metalloproteinases. Pharmaceuticals, 2017, 10, 49. | 1.7 | 7 |
| 173 | Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on ^{13}F -fluorinated β -sulfonylamino hydroxamic acid. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 10. | 1.8 | 7 |
| 174 | A Multifunctional HBED-Type Chelator with Dual Conjugation Capabilities for Radiopharmaceutical Development. Synlett, 2019, 30, 1795-1798. | 1.0 | 7 |
| 175 | Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 510-522. | 0.5 | 7 |
| 176 | Rhenium and technetium-complexed silicon rhodamines as near-infrared imaging probes for bimodal SPECT- and optical imaging. Dalton Transactions, 2020, 49, 7294-7298. | 1.6 | 7 |
| 177 | Dual-Labeling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives. Pharmaceuticals, 2022, 15, 432. | 1.7 | 7 |
| 178 | Radiosynthesis of a ^{68}Ga labeled matrix metalloproteinase inhibitor as a potential probe for PET imaging. Applied Radiation and Isotopes, 2012, 70, 1723-1728. | 0.7 | 6 |
| 179 | Efficient synthesis of a fluorine-18 labeled biotin derivative. Nuclear Medicine and Biology, 2012, 39, 1189-1194. | 0.3 | 6 |
| 180 | Future trends in prostate cancer theranostics with PSMA ligands. Clinical and Translational Imaging, 2016, 4, 487-489. | 1.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Synthesis of a dihalogenated pyridinyl silicon rhodamine for mitochondrial imaging by a halogen dance rearrangement. <i>Beilstein Journal of Organic Chemistry</i> , 2019, 15, 2333-2343. | 1.3 | 6 |
| 182 | Deuteration <i>versus</i> ethylation â€“ strategies to improve the metabolic fate of an ¹⁸F-labeled celecoxib derivative. <i>RSC Advances</i> , 2020, 10, 38601-38611. | 1.7 | 6 |
| 183 | Development of the First Potential Nonpeptidic Positron Emission Tomography Tracer for the Imaging of CCR2 Receptors. <i>ChemMedChem</i> , 2021, 16, 640-645. | 1.6 | 5 |
| 184 | Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer. <i>Pharmaceuticals</i> , 2021, 14, 188. | 1.7 | 5 |
| 185 | Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 425-36. | 1.0 | 5 |
| 186 | Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. <i>Molecular Pharmaceutics</i> , 2022, 19, 2231-2247. | 2.3 | 5 |
| 187 | [18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 111-113. | 0.9 | 4 |
| 188 | Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 103-105. | 0.9 | 4 |
| 189 | A new approach to silicon rhodamines by Suzukiâ€™Miyaura coupling â€“ scope and limitations. <i>Beilstein Journal of Organic Chemistry</i> , 2019, 15, 2569-2576. | 1.3 | 4 |
| 190 | Radiolabeled Silicon-Rhodamines as Bimodal PET/SPECT-NIR Imaging Agents. <i>Pharmaceuticals</i> , 2021, 14, 1155. | 1.7 | 4 |
| 191 | 18F-Labeled Small-Molecule and Low-Molecular-Weight PET Tracers for the Noninvasive Detection of Cancer. <i>Recent Results in Cancer Research</i> , 2020, 216, 283-318. | 1.8 | 3 |
| 192 | Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity. <i>Molecular Imaging and Biology</i> , 2022, 24, 434-443. | 1.3 | 3 |
| 193 | Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, . | 0.7 | 3 |
| 194 | Quantitation of the A2A Adenosine Receptor Density in the Striatum of Mice and Pigs with [18F]FLUDA by Positron Emission Tomography. <i>Pharmaceuticals</i> , 2022, 15, 516. | 1.7 | 3 |
| 195 | 3-[123I]Iodo-L-Î±-methyl tyrosine transport into human fibroblasts and comparison with Ewingâ€™s sarcoma cells. <i>Nuclear Medicine and Biology</i> , 2002, 29, 483-490. | 0.3 | 2 |
| 196 | Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1580-1595. | 1.1 | 2 |
| 197 | Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. <i>British Journal of Radiology</i> , 2011, 84, S168-S178. | 1.0 | 2 |
| 198 | Non-peptidyl 18F-Labelled PET Tracers as Radioindicators for the Noninvasive Detection of Cancer. <i>Recent Results in Cancer Research</i> , 2013, 187, 107-132. | 1.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Pharmaceuticalsâ€”Special Issue on Radiopharmaceutical Chemistry between Imaging and Endoradiotherapy. Pharmaceuticals, 2014, 7, 839-849. | 1.7 | 2 |
| 200 | Radiopharmaceutical Sciences. , 2020, , 49-191. | | 2 |
| 201 | Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mLDH1 Mutant Tumours. Molecules, 2022, 27, 3766. | 1.7 | 2 |
| 202 | 18Fâ€”Labeled PETâ€”Tracers for Cardiological Imaging. , 2008, , 85-139. | | 1 |
| 203 | Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics. Clinical and Translational Imaging, 2014, 2, 33-41. | 1.1 | 1 |
| 204 | Epoxyeicosatrienoic acids (EETs) form adducts with DNA in vitro. Prostaglandins and Other Lipid Mediators, 2016, 123, 63-67. | 1.0 | 1 |
| 205 | Reply: PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al ¹⁸ F ²⁺ . Journal of Nuclear Medicine, 2017, 58, 2041-2041. | 2.8 | 1 |
| 206 | Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership. Radiotherapy and Oncology, 2018, 129, 387-388. | 0.3 | 1 |
| 207 | Designing tracers for PET imaging of the urokinaseâ€”type plasminogen activator receptor from a cyclic uPAâ€”derived peptide: first in vitro evaluations. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 483-494. | 0.5 | 1 |
| 208 | Highlight selection of radiochemistry and radiopharmacy developments by editorial board (Januaryâ€”June 2020). EJNMMI Radiopharmacy and Chemistry, 2021, 6, 5. | 1.8 | 1 |
| 209 | Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 13. | 1.8 | 1 |
| 210 | Novel radiolabeled silicon rhodamine dyes for bimodal scintigraphic and optical imaging. , 0, , . | | 1 |
| 211 | Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate Cancer. , 2017, , 51-58. | | 1 |
| 212 | Non-Invasive Assessment of Locally Overexpressed Human Adenosine 2A Receptors in the Heart of Transgenic Mice. International Journal of Molecular Sciences, 2022, 23, 1025. | 1.8 | 1 |
| 213 | A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer. Pharmaceuticals, 2022, 15, 267. | 1.7 | 1 |
| 214 | Automated radiosynthesis of the adenosine A _{2A} receptorâ€”targeting radiotracer [¹⁸ F]FLUDA. Journal of Labelled Compounds and Radiopharmaceuticals, 2022, , . | 0.5 | 1 |
| 215 | Prognostic Significance of Amino Acid Transport Imaging in Patients with Brain Tumors. Neurosurgery, 2002, 50, 958-965. | 0.6 | 0 |
| 216 | MP53-08 THE DIAGNOSTIC VALUE OF 68 GA-LABELLED PSMA-LIGAND PET/CT IN MEN WITH RECURRENT PROSTATE CANCER. Journal of Urology, 2015, 193, . | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Development of bispecific theranostic ligand targeting the prostate specific membrane antigen (PSMA) and gastrin releasing peptide (GRPR) receptor. Nuclear Medicine and Biology, 2021, 96-97, S29-S30. | 0.3 | 0 |
| 218 | The radiolabeling of silicon rhodamines for multimodal PET/ SPECT- and NIR optical imaging. Nuclear Medicine and Biology, 2021, 96-97, S81. | 0.3 | 0 |
| 219 | ¹³¹ Ba as a promising SPECT-diagnostic match for ²²³ / ²²⁴ Radium. Nuclear Medicine and Biology, 2021, 96-97, S95. | 0.3 | 0 |
| 220 | ¹¹ C-Methionine Uptake in the Lactating Human Breast. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, e66-e67. | 0.7 | 0 |
| 221 | Abstract 3719: Bicyclic peptides for PET imaging of MT1-MMP expressing tumors. , 2017, , . | | 0 |
| 222 | Procedures for the GMP-Compliant Production and Quality Control of [¹⁸ F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. , 0, , . | | 0 |
| 223 | Clickable albumin binders to modulate pharmacokinetic properties of theranostic radioligands. , 0, , . | | 0 |
| 224 | Barium-131 as starting point for the development of radiotheranostic approaches. , 0, , . | | 0 |
| 225 | Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [¹⁸ F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. Pharmaceuticals, 2022, 15, 324. | 1.7 | 0 |